EMA Authorised: Brimica Genuair (formoterol fumarate dihydrate;aclidinium bromide) — Covis Pharma Europe B.V.

View source ↗

Summary

The EMA authorized Brimica Genuair, a fixed-dose inhalation product containing formoterol fumarate dihydrate and aclidinium bromide, for chronic obstructive pul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Brimica Genuair (formoterol fumarate dihydrate; aclidinium bromide)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: Covis Pharma Europe B.V.. Decision date: 20/02/2025